- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01371487
GSK1120212 Food-effect Study
An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors
Studie Overzicht
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- GSK Investigational Site
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78229
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- Male or female; 18 years of age or older at the time of consent
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Able to swallow and retain oral medication.
- Histologically or cytologically confirmed diagnosis of a solid tumor.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Appendix 3).
Adequate baseline organ function defined in Table 5 Definitions for Adequate Baseline Organ Function Absolute neutrophil count greater than or equal to 1.2 × 109/L Hemoglobin greater than or equal to9 g/dL Platelets greater than or equal to 75 × 109/L Prothrombin time (PT), International normalization ratio (INR)a and Partial thromboplastin time (PTT) less than or equal to 1.5 times ULN Hepatic Total bilirubin less than or equal to 1.5 times ULN ALT less than or equal to 2.5 times ULN Renal Creatinine or less than or equal to 1.5 times ULN Calculated creatinine clearance or greater than or equal to 50 mL/min 24-hour urine creatinine clearance greater than or equal to 50 mL/min Cardiac LVEF greater than or equal to LLNc by ECHO or MUGA
- INR greater than 1.5 times ULN will be acceptable in case of subjects receiving therapeutic anticoagulants such as warfarin as long as INR is monitored during the study according to clinical practice.
- Calculated by the Cockcroft-Gault formula (see Appendix 2).
- If LLN is not defined for a given institution, then ejection fraction must be greater than or equal to 50%.
- Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception, as defined in Section 7.1.1, during the study and for 6 weeks following the last dose of study treatment.
- Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in Section 7.1.2 from the time of the first dose of study treatment until 16 weeks following the last dose of study treatment (based on the lifecycle of sperm).
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Currently receiving cancer therapy (e.g., chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) within 3 weeks prior to randomization; chemotherapy regimens without delayed toxicity within 2 weeks prior to randomization; or use of an investigational anti-cancer drug within 4 weeks prior to randomization.
- Has unresolved Grade 2 or greater toxicity (based on NCI-CTCAE, version 4.0) [NCI Common Terminology Criteria for Adverse Events, 2009] from previous anti-cancer therapy except Grade 2 decreased hemoglobin levels or alopecia.
- Has pre-existing peripheral neuropathy of greater than or equal to Grade 2.
- Has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer, prior to the first dose of study treatment in this study.
- Has participated in a study that resulted in or made a donation of blood or blood products in excess of 500 mL within 56 days of the first dose of study treatment.
- Has presence of active GI disease or other condition (e.g., gastrectomy, bariatric surgery, small or large bowel resection, or cholecystectomy should be excluded) that may interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.
- Has any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures, in the opinion of the investigator or GSK Medical Monitor.
- Has a history of interstitial lung disease or pneumonitis.
Is currently using a prohibited medication(s) or requires the use of any of the prohibited medications during the study (see Section 8.2).
• NOTE: Use of anticoagulants such as warfarin is permitted; however, INR must be monitored in accordance with local institutional practice.
Has a history or current evidence/risk of RVO or CSR:
- History of RVO or CSR, or predisposing factors to RVO or CSR (i.e., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension or diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)
- Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping
- Intraocular pressure greater than 21 mmHg as measured by tonography
Has symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression
- Note: Subjects previously treated for these conditions that have had stable central nervous system (CNS) disease (verified with consecutive imaging studies) for greater than 3 months, are asymptomatic and are not currently taking corticosteroids, or are on stable dose of corticosteroids for at least 1 month prior to Day 1 of the study are permitted.
- Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs (EIAEDs).
- Has a QtcB or QTcF (preferred) greater than or equal to 480 msec.
- Has a history or evidence of cardiovascular risk including any of the following:
- History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for greater 30 days prior to randomization are eligible.
- History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
- History or evidence of current greater than or equal to Class II congestive heart failure as defined by New York Heart Association (NYHA) (Appendix 4).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment A
GSK1120212 Dose /Treatment 2.0 mg/Fasted
|
Oral/once-daily single doses on Day 1 of Periods 1 and 2
|
Experimenteel: Treatment B
GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
|
Oral/once-daily single doses on Day 1 of Periods 1 and 2
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
evaluate the effect of a high-fat, high-calorie meal on the PK of a single dose of GSK1120212 administered to subjects
Tijdsspanne: Predose - 168 hours post dose period 1 and 2
|
• Area under the plasma concentration-time curve from time zero (pre-dose) to time t (AUC(0-t)), AUC(0-inf), Cmax, and tmax.
|
Predose - 168 hours post dose period 1 and 2
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
assess the short-term safety and tolerability of single oral doses of 2.0 mg of GSK1120212 administered to subjects
Tijdsspanne: Day 1/periods 1 and 2, Day 8 period 2 and follow-up.
|
vital signs, electrocardiograms (ECGs), clinical laboratory tests, and AEs
|
Day 1/periods 1 and 2, Day 8 period 2 and follow-up.
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 113709
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op GSK1120212
-
Novartis PharmaceuticalsBeëindigdKankerFrankrijk, Verenigde Staten, Nederland, Canada, Taiwan, Korea, republiek van
-
National Cancer Institute (NCI)Actief, niet wervendGeavanceerd maligne solide neoplasma | Gemetastaseerd maligne solide neoplasma | Gemetastaseerd maligne neoplasma in de lever | Inoperabel solide neoplasmaVerenigde Staten, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupActief, niet wervendJuveniele myelomonocytaire leukemie | Neurofibromatose type 1Verenigde Staten
-
National Cancer Institute (NCI)VoltooidLokaal gevorderd epithelioïde hemangio-endothelioom | Gemetastaseerd epithelioïde hemangio-endothelioom | Inoperabel epithelioïde hemangio-endothelioomVerenigde Staten
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer FoundationActief, niet wervendGemetastaseerd prostaatcarcinoom | Recidiverend prostaatcarcinoom | Stadium IV prostaatkanker | Hormoonresistente prostaatkankerVerenigde Staten
-
National Cancer Institute (NCI)VoltooidRefractair plasmacelmyeloom | Recidiverend plasmacelmyeloomCanada
-
National Cancer Institute (NCI)VoltooidStadium IV oogmelanoom AJCC v7 | Terugkerend oogmelanoomVerenigde Staten, Frankrijk, Verenigd Koninkrijk
-
National Cancer Institute (NCI)BeëindigdTerugkerende volwassen acute myeloïde leukemie | Onbehandelde volwassen acute myeloïde leukemieVerenigde Staten
-
National Cancer Institute (NCI)GlaxoSmithKlineVoltooidStadium IV borstkanker | Recidiverend mammacarcinoom | Invasief mammacarcinoom | Oestrogeenreceptor negatief | HER2/Neu-negatief | Progesteronreceptor negatief | Triple-negatief borstcarcinoomVerenigde Staten
-
National Cancer Institute (NCI)NRG OncologyVoltooidEndometrium Clear Cell Adenocarcinoom | Endometrium adenocarcinoom met gemengde cellen | Endometrium sereus adenocarcinoom | Endometrium ongedifferentieerd carcinoom | Endometrium Adenocarcinoom | Terugkerende baarmoedercorpuskankerVerenigde Staten